cfa-mir-130b: cfa-mir-130b, a microRNA, has been identified as a more accurate biomarker than NT-proBNP for distinguishing dogs with various heart diseases from healthy dogs, particularly in MMVD stage B, PDA, and PS groups [PMC8542680]. It is significantly upregulated in these groups and shows a strong positive correlation with heart rate, NT-proBNP levels, and LA/Ao ratio in MMVD stage B [PMC8542680]. The upregulation of cfa-mir-130b is consistent across different types of cardiac hypertrophy and may reflect common pathophysiological changes induced by heart diseases [PMC8542680]. Despite its potential as an early diagnostic biomarker for cardiac conditions in dogs, cfa-mir-130b's specific target genes and pathways remain to be elucidated [PMC8542680]. Furthermore, its expression does not significantly change in advanced stages of MMVD (stages C and D), suggesting that it may not be a reliable marker across all stages of the disease [PMC8542680]. However, the consistent upregulation of cfa-mir-130b in early disease stages underscores its potential utility for early detection and monitoring of canine heart diseases [PMC8542680].